Banner Alzheimer’s Institute has received $10 million in new research funding through the Alzheimer’s Association, in partnership with the GHR Foundation and Fidelity Biosciences Research Initiative. The new funding is in support of a groundbreaking Alzheimer’s disease prevention trial set to launch later this year.
The $10 million supports the Alzheimer’s Prevention Initiative (API), which is led by BAI, and further bolsters a trial focused on determining whether therapies targeting amyloid proteins in the brain may prevent or delay Alzheimer’s symptoms in people at high genetic risk for developing the disease at older ages.
This extraordinary support from the Alzheimer’s Association, partnered with the commitment of many other organizations including philanthropic donations through the Banner Alzheimer’s Foundation and the U.S. National Institutes of Health, will help make it possible to evaluate two promising Alzheimer’s prevention therapies and do so in a way that will help the entire field find treatments that work as soon as possible. Further, this new funding brings the Banner Alzheimer’s Foundation to within $1 million of their $40 million fund-raising campaign on behalf of BAI.
Congratulations to API’s leadership, BAI’s executive director Eric Reiman, MD, director Pierre Tariot, MD, and principal scientist Jessica Langbaum, PhD.
